A Phase III trial is evaluating livmoniplimab (an anti-leucine-rich repeat containing 32 (LRRC32)/TGF-β1 monoclonal antibody) plus a PD-1 inhibitor in advanced HCC. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.